TerminatedPhase 2NCT03225287
Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study
Studying Paroxysmal nocturnal hemoglobinuria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ra Pharmaceuticals, Inc.
- Principal Investigator
- Dr. Anita Hill, M.DSt James' Institute of Oncology
- Intervention
- Zilucoplan (RA101495)(drug)
- Enrollment
- 19 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2021
Study locations (12)
- Investigative Site 4, Los Angeles, California, United States
- Investigative Site 19, Dallas, Texas, United States
- Investigative Site 3, Gosford, Australia
- Investigative Site 5, Melbourne, Australia
- Investigative Site 10, Toronto, Canada
- Investigative Site 14, Helsinki, Finland
- Investigative Site 9, Ulm, Germany
- Investigative Site 17, Budapest, Hungary
- Investigative Site 13, Christchurch, New Zealand
- Investigative Site 12, Hamilton, New Zealand
- Investigative Site 6, Leeds, United Kingdom
- Investigative Site 7, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03225287 on ClinicalTrials.govOther trials for Paroxysmal nocturnal hemoglobinuria
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07154745A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working EfficientlyRegeneron Pharmaceuticals
- RECRUITINGNCT07457151Danicopan PMS in KoreaAstraZeneca
- RECRUITINGPHASE1NCT07462780A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy ParticipantsShenzhen Kangzhe Biotechnology Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07470762Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal HemoglobinuriaJiangsu Hansoh Pharmaceutical Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07187401A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 InhibitorRegeneron Pharmaceuticals
- ACTIVE NOT RECRUITINGNCT07413250Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry DataAlexion Pharmaceuticals, Inc.
- RECRUITINGNCT07229235REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal HemoglobinuriaNovartis Pharmaceuticals
- RECRUITINGPHASE3NCT06934967Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH PatientsNovartis Pharmaceuticals